215 results on '"Afzali, Anita"'
Search Results
2. Unmet Needs in Real-World Advanced Therapy-Naïve and -Experienced Patients with Moderately to Severely Active Ulcerative Colitis in the United States
3. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
4. Indications and safety of newer IBD treatments in the older patient
5. Surgery for Crohn’s Disease Is Associated With a Dysbiotic Microbiome and Metabolome: Results From Two Prospective Cohorts
6. Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry
7. Pregnant women with immune mediated inflammatory diseases who discontinue biologics have higher rates of disease flare
8. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program
9. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
10. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
11. The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable
12. Women’s Health and Ulcerative Colitis
13. Predicting Post-operative Complications in Crohn’s Disease: an Appraisal of Clinical Scoring Systems and the NSQIP Surgical Risk Calculator
14. A women-focused matrix mentorship programme in gastroenterology
15. Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension.
16. Inflammatory Bowel Disease in the Baby to Baby Boomer: Pediatric and Elderly Onset of IBD
17. Opioid Use Is Associated With Higher Health Care Costs and Emergency Encounters in Inflammatory Bowel Disease
18. Acute Myelogenous Leukemia as a Rare Cause of Duodenal Ulcers
19. Inflammatory bowel disease during pregnancy: management of a disease flare or remission
20. To the Editors: Index Severity Score and Early Readmission Predicts Increased Mortality in Crohn’s Disease Patients
21. Index Severity Score and Early Readmission Predicts Increased Mortality in Ulcerative Colitis Patients
22. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: A single academic center case series
23. Update on MR Enterography: Potentials and Pitfalls
24. Challenges in Using Real-world Clinical Practice Records for Validation of Clinical Trial Data in Inflammatory Bowel Disease: Lessons Learned
25. EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 & 3 PHASE 3 STUDIES
26. Su1792 EFFICACY OUTCOMES OF PLACEBO MAINTENANCE TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO RESPONDED TO PLACEBO INDUCTION THERAPY: RESULTS FROM THE PHASE 3 COMMAND STUDY
27. Su1797 ETRASIMOD SHOWS LOW RISK OF ADVERSE EVENTS FOLLOWING CONCOMITANT USE WITH OPIOIDS OR ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS
28. Reply
29. Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting.
30. A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and Persistence With Inflammatory Bowel Disease Therapy (ASSIST Study): Protocol for a Randomized Controlled Trial.
31. Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel.
32. 63 TRENDS IN RACIAL DISPARITIES IN SURGICAL CARE FOR IBD PATIENTS
33. Tu1799 ASSOCIATION OF EARLY CLINICAL EFFICACY FACTORS WITH 1-YEAR RESPONSE AND REMISSION TO TOFACITINIB IN MODERATE TO SEVERE ULCERATIVE COLITIS IN A REAL WORLD PROSPECTIVE MULTICENTER STUDY (TOUR)
34. Tu1725 EFFECTS OF OZANIMOD ON HISTOLOGIC REMISSION AND MUCOSAL HEALING OVER 3 YEARS OF CONTINUOUS TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS
35. Tu1707 CORTICOSTEROID-FREE CLINICAL REMISSION RATES WITH GUSELKUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 48 ANALYSES FROM THE PHASE 2B GALAXI 1 STUDY
36. Su1023 MOVING THE NEEDLE FOR WOMEN IN GASTROENTEROLOGY: ACQUIRING LEADERSHIP SKILLS FOR CAREER GROWTH!
37. 950 LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
38. Excellent Posttransplant Survival for Patients with Nonalcoholic Steatohepatitis in the United States
39. Impact of Cannabis Use on Inpatient Inflammatory Bowel Disease Outcomes in 2 States Legalizing Recreational Cannabis.
40. International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey.
41. Gender barriers are worsening women's access to health care in Afghanistan
42. Tu1458: LONG-TERM USE OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
43. Tu1450: EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
44. Tu1472: RAPIDITY OF OZANIMOD-INDUCED SYMPTOMATIC RESPONSE AND REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE INDUCTION PERIOD OF TRUE NORTH
45. Su1505: IMPACT OF CONCOMITANT PROTON PUMP INHIBITOR AND ADVANCED THERAPY USE ON HEALTH OUTCOMES OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
46. Su1510: IDENTIFYING THE MOST EFFECTIVE TREATMENT ALGORITHM FOR THERAPIES TO TREAT MODERATE TO SEVERE ULCERATIVE COLITIS
47. 969: RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
48. 888: EFFICACY AND SAFETY OF GUSELKUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 48 ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY
49. Health Maintenance Consensus for Adults With Inflammatory Bowel Disease.
50. IDENTIFYING THE MOST EFFECTIVE TREATMENT ALGORITHM FOR THERAPIES TO TREAT MODERATE TO SEVERE ULCERATIVE COLITIS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.